The Genomics Revolution

In this episode of The Genomics Revolution, host Sian Jarvis is joined by Vincent Plagnol, Chief Scientific Officer of Genomics Limited. Together, they delve into the transformative impact of genomics on modern drug development. Discover how genomics is not only de-risking the process but also significantly reducing costs, allowing for more efficient drug discovery. Vincent shares insights on the complexities of genetic variations, the role of data in understanding human biology, and how AI is enhancing the ability to interpret vast amounts of genetic information. Tune in for an enlightening discussion on the future of healthcare through the lens of genomics!For more information, visit Genomics: https://genomics.com/Chapters:(00:00) Genomics Revolution explores how genomics is revolutionizing drug development(01:13) Genomics is a relatively new branch of science exploring human biology(05:27) Can you paint a picture for me about the complexity of genomics(14:00) 95% of drug development failures are due to genetic factors(15:42) Different Pharma have bet on genetics at different parts of their journey(16:35) How does AI help in tackling complex scientific problems such as drug targeting(20:50) Vincent believes genomics holds key to the answer to so many diseases

In this episode of the Genomics Revolution, host Sian Jarvis is joined by Chief Medical Officer Seamus Harrison to discuss the transformative power of genomics in healthcare. They delve into the NHS HEART Trial and the role of polygenic risk scores in predicting and preventing cardiovascular disease. Discover how genomics is shifting the focus from reactive treatment to proactive prevention, and learn about the potential to save lives by identifying invisible risk factors that affect one in five people.For more information, visit Genomics: https://genomics.com/Chapters:(00:00) Genomics Revolution explores how genomics is transforming healthcare(02:13) Many common diseases are driven by, uh, genetic factors(08:55) Q: Evidence is critical when introducing new medical technologies(15:02) Evidence that we can engage individuals with their cardiovascular risk is encouraging(17:31) Almost all common diseases are genetic in some component

In this inaugural episode of The Genomics Revolution, host Sian Jarvis is joined by Professor Sir Peter Donnelly, a leading expert in genomics and the founder of Genomics Ltd. Together, they discuss the transformative impact of genomics on drug discovery and healthcare, exploring how genetic insights can lead to more personalised medicine and improved health outcomes. From understanding individual disease risks to enhancing drug development success rates, this episode uncovers the revolutionary potential of genomics in reshaping our approach to drug development. For more information, visit Genomics: https://genomics.com/Chapters:(00:00) Genomics Revolution explores how genomics can transform health and drug discovery(03:41) 95% of drugs fail during drug development process, according to research(09:42) You talked about how genomics can help drug discovery(13:19) Why is there so much hesitation around the adoption of genomics(17:00) How can we use genomics to improve health outcomes(24:45) Next step is to roll out these technologies in cardiovascular prevention(25:29) Genetics is a major driver of the likelihood of a person becoming obese